Accelerate PhenoTest™ BC Kit

Timing is everything
for some patients

Accelerate PhenoTest™ BC Kit –

Independent studies show the BC kit provides identification and susceptibility results with MICs an average of 40 hours faster than the current standard of care methods.*

*see publicatons

Get the details on the evaluation and verification program:
Reserve your spot now

 

Admitted Sunday.
MIC results Monday.

The Accelerate PhenoTest™ BC Kit makes earlier optimal therapy possible by providing answers, directly from positive blood cultures, that drive treatment decisions 1-2 days faster than current methods allow today.

Earlier optimal therapy can lead to reduced cost of patient care, fewer adverse incidents, lower rate of resistance, and better clinical outcomes.

Clinical relevancy

Timely escalation to effective therapy reduces mortality

Impact of Time to Definitive Therapy on Mortality4
Empiric therapy may not be adequate in up to 25% of patients with bloodstream infections (BSIs).4 Shortening the time horizon from empiric to optimal therapy requires susceptibility results with the MIC for 52% of patients with BSIs.5

4 Retamar et al. Antimicrob Agents Chemother. 2012 Jan;56(1):472-8
5 Huang et al. Clin Infect Dis. 2013 Nov;57(9):1237-45

Timely escalation to effective therapy reduces hospital length of stay

Impact of Effectiveness of Antibiotic on Hospital Length of Stay (Gram-negative sepsis)6
Reducing hospital length of stay (LOS) by two days reduces broad spectrum antibiotic exposure that may increase the risk of HAIs, C. difficile infection, and increase risk of community-acquired resistance. It also substantially reduces cost of care.

6 Shorr et al, Crit Care Med 2011. Jan; 39(1): 46-51

De-escalation can improve patient outcomes

% CDI Incidence by Number of Simultaneous Drug Classes Administered

Reducing the time frame from empiric broad-spectrum antibiotic coverage to optimal therapy has been shown to dramatically reduce the incidence of C. difficile in patients with BSIs.7

Reporting antimicrobial susceptibility results 1-2 days faster gives clinicians the data required to move to targeted optimal therapy faster.

7 Tartof et al, 2015. Infect. Control Hosp. Epidemiol. 2015;36(12) :1409–1416

Sensible economics

Potential economic impact across a hospital system serviced by a centralized microbiology lab*
$4.8k
net savings per patient tested
1.7k
fewer ICU days
each year
$10.8m
net financial impact to hospital system
*Estimated healthcare outcome and economic impact based on model of first full year of testing on positive blood culture samples.
Walk me through this

Gram-Positive

Identification
Ampicilin
Ceftaroline
Erythromycin
Daptomycin
Linezolid
Vancomycin
Methicillin
resistance
(Cefoxitin)
MLSb
(Erythromycin-
Clindamycin)
S. aureus
S. lugdunensis
CNS spp.
E. faecalis
E. faecium
Streptococcus spp.
Resistance
Phenotypes
S. aureusS. lugdunensisCNS spp.E. faecalisE. faeciumStreptococcus spp.
Identification
Ampicilin
Ceftaroline
Erythromycin
Daptomycin
Linezolid
Vancomycin
Methicillin resistance (Cefoxitin)
Resistance Phenotypes
MLSb (Erythromycin-Clindamycin)

Gram-Negative

Identification
Ampicillin-
Sulbactam
Piperacillin-
Tazobactam
Cefepime
Ceftazidime
Ceftriaxone
Ertapenem
Meropenem
Amikacin
Gentamicin
Tobramycin
Ciprofloxacin
Aztreonam
E. coli
Klebsiella spp.
Enterobacter spp.
Proteus spp.
Citrobacter spp.
S. marcescens
P. aeruginosa
A. baumannii
E. coliKlebsiella spp.Enterobacter spp.Proteus spp.Citrobacter spp.S. marcescensP. aeruginosaA. baumannii
Identification
Ampicillin-
Sulbactam
Piperacillin-
Tazobactam
Cefepime
Ceftazidime
Ceftriaxone
Ertapenem
Meropenem
Amikacin
Gentamicin
Tobramycin
Ciprofloxacin
Aztreonam

Yeast

Identification
Candida albicans
Candida glabrata
 

Klebsiella spp.
K. oxytoca
K. pneumoniae

Enterobacter spp.
E. cloacae
E. aerogenes

Proteus spp.
P. mirabilis
P. vulgaris

Citrobacter spp.
C. freundii
C. koseri

CNS spp.
S. capitis
S. epidermidis
S. haemolyticus
S. hominis
S. lugdunensis
S. warneri

Streptococcus spp.
S. agalactiae
S. gallolyticus
S. mitis
S. oralis
S. pneumoniae

 
 

Specifications

48-channel disposable test cassette
Reagent cartridge
Sample vial

The Accelerate PhenoTest™ BC kit is run directly with positive blood culture samples.
Store BC kits at 2-8°C. Do not store at room temperature.

1 Kit

Dimensions:
2.5 h x 8 w 12 l in
6.2 h x 20 w x 30 l cm

Weight:
2.1 lb
950 g

Storage: 2.8°C

5 Pack, including packaging

Dimensions:
13 h x 12.5 w x 13 l in
33 h x 32.5 w x 33 l cm

Weight:
33 lb
15 kg

Publications

Feb 27, 2019

Evaluation of the Accelerate Pheno™ System for identification of Acinetobacter clinical isolates and minocycline susceptibility testing
Journal of Clinical Microbiology

Jan 16, 2019

Performance of the Accelerate Diagnostics Pheno™ system with resin-containing BacT/ALERT® Plus blood culture bottles
Diagnostic Microbiology and Infectious Disease

Jan 02, 2019

Clinical Effect of Expedited Pathogen Identification and Susceptibility Testing for Gram-Negative Bacteremia and Candidemia by Use of the Accelerate Pheno™ System
The Journal of Applied Laboratory Medicine

Dec 18, 2018

The Hypothetical Impact of Accelerate Pheno (ACC) on Time to Effective Therapy and Time to Definitive Therapy for bloodstream infections due to drug-resistant Gram-negative bacilli.
Antimicrobial Agents and Chemotherapy

See all publications